Poor aqueous solubility remains one of the leading causes of delay in small-molecule development, yet it is rarely a single problem. Low equilibrium solubility, slow dissolution, precipitation, poor wettability and high crystal-lattice energy each call for a different solution. Codis Rapid Screen is a molecule-led, technology-agnostic framework that identifies the dominant constraint, compares enabling technologies, including amorphous solid dispersions, lipid-based formulations, particle-size reduction and cyclodextrin complexation, and assesses prototypes against the intended preclinical use.
In this whitepaper, discover how Rapid Screen reduces formulation-related uncertainty before pharmacokinetic (PK) evaluation, so early PK studies yield interpretable evidence that supports confident candidate progression.
Learn more about Codis by visiting Codis.com.